Onco-Innovations Announces Closing of Private Placement

Executive Summary

• Onco‑Innovations Limited closed a non‑brokered private placement, issuing 1,870,000 units at $0.65 per unit for total gross proceeds of $1,215,500.
• Each unit consists of one common share and one warrant to purchase an additional share at $0.75 exercisable until March 12 2029.
• Proceeds will be used for general corporate and working‑capital purposes, including research & development and investor‑relations activities.

Key Details

• Units Issued: 1,870,000 units @ $0.65 per unit → Gross proceeds: $1,215,500.
• Unit Composition: 1 common share + 1 common share purchase warrant.
• Warrant Terms: Right to purchase one share at $0.75 per share; exercisable for three years, expiring on March 12 2029.
• Administrative Shares: 18,700 shares issued as consideration for administrative services related to the private placement.
• Use of Proceeds: General corporate and working‑capital purposes, including operational objectives, R&D programs, and investor‑relations initiatives.
• Statutory Hold Period: All securities subject to a hold period of four months and one day under applicable securities laws.
• U.S. Offering Restrictions: Securities not registered under the U.S. Securities Act; cannot be offered or sold in the United States absent exemption or registration.

Notable Quotes

• “We are pleased to close this financing, which provides us with essential capital to advance our oncology research and support our growth initiatives.” – Thomas O'Shaughnessy, Chief Executive Officer.